12:00 AM
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Actemra regulatory update

Roche disclosed in its 4Q12 earnings that it submitted applications for a subcutaneous formulation of tocilizumab to EMA and FDA to treat moderate to severe rheumatoid arthritis in December 2012. An IV formulation...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >